535 related articles for article (PubMed ID: 21575503)
1. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Zhao WY; Chen DY; Qi Q
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
[TBL] [Abstract][Full Text] [Related]
2. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
[TBL] [Abstract][Full Text] [Related]
3. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
[TBL] [Abstract][Full Text] [Related]
8. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
10. [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Dong NN; Wang MY; Zhang Q; Liu ZF
Ai Zheng; 2009 Apr; 28(4):412-5. PubMed ID: 19622303
[TBL] [Abstract][Full Text] [Related]
11. [Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
Liu Y; Kang MF; Luo MQ; Dong CM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov; 30(11):2575-6. PubMed ID: 21097437
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
von Moos R; Roth A; Ruhstaller T; Widmer L; Uhlmann C; Cathomas R; Köberle D; Simcock M; Lanz D; Popescu R
Onkologie; 2010; 33(6):295-9. PubMed ID: 20523092
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer.
Bajetta E; Verzoni E; Ferrario E; Dotti K; Gevorgyan A; Celio L
Tumori; 2009; 95(1):43-7. PubMed ID: 19366055
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Luo HY; Wang ZQ; Wang FH; Qiu MZ; Teng KY; Ruan DY; He YJ; Li YH; Xu RH
Am J Clin Oncol; 2011 Dec; 34(6):555-60. PubMed ID: 22101386
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
